Publication date: May 13, 2019
This post was originally published on this site Early, one-year data from the Phase 3 CHORDS study show that Ocrevus effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who have had poor responses to other disease-modifying therapies. These interim results were presented at the 2019 annual meeting of the American Academy of Neurology (AAN) in the presentation, -One-year interim analysis results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments. ” The CHORDS trial (NCT02637856) is evaluating whether Ocrevus (ocrelizumab, marketed by Genentech) might be an effective therapy for RRMS patients who had not responded well to an -adequate course” of other MS therapies. -Findings from this interim analysis of all 608 patients at one year of follow-up support the effectiveness of Ocrevus” in treating people with a suboptimal response to other DMTs, Leist concluded. The post #AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data Suggest appeared first on Multiple Sclerosis News Today.
|drug||DRUGBANK||Antithymocyte immunoglobulin (rabbit)|
|disease||DOID||urinary tract infection|
|disease||MESH||urinary tract infection|
|disease||MESH||relapsing-remitting multiple sclerosis|
- #AANAM – Greater Exposure to Ocrevus Means Less Risk of Disability Progression in MS Patients, Study Contends
- #AANAM – Oral Ozanimod Better than Avonex in Lessening Brain Volume Loss in Relapsing MS, Trial Shows
- Emerging oral immunomodulating agents – focus on teriflunomide for the treatment of multiple sclerosis.
- #AANAM – RRMS Patients Switching to Lemtrada Report Greater Satisfaction with Treatment and Improvements in Quality of Life